<?xml version="1.0" encoding="utf-8" ?>
<INTERACTIONS>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>25-ALLOPURINOL.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ALLOPURINOL" rxcui="519">
<ATC code="M04AA01" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="VITAMIN K ANTAGONISTS" code="B01AA-001" /></DRUG2>
<DESCRIPTION>Increase of the effect of the Vitamin K antagonist and of the risk of hemorrhage (decrease of its hepatic metabolism)

</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>More frequent testing of the INR. Possible adjustment of the dosage of the vitamin K antagonist during the treatment with the allopurinol and a week after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>25-ALLOPURINOL.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ALLOPURINOL" rxcui="519">
<ATC code="M04AA01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="DIDANOSINE" rxcui="3364">
<ATC code="J05AF02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of didanosine and of its undesirable effects

</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>25-ALLOPURINOL.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ALLOPURINOL" rxcui="519">
<ATC code="M04AA01" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="AMINOPENICILLINS" code="J01CA" /></DRUG2>
<DESCRIPTION>Increased risk of cutaneous reactions

</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>25-ALLOPURINOL.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ALLOPURINOL" rxcui="519">
<ATC code="M04AA01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="VIDARABINE" rxcui="11194">
<ATC code="S01AD06" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of neurological disorders (trembling, confusion) due to partial inhibition of the metabolism of the antiviral</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
</INTERACTIONS>
